Treatment of Tuberculosis Meningitis

Introduction to Treatment Regimens

• The American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America recommend a 9-12 month treatment regimen with isoniazid, rifampicin, pyrazinamide, and ethambutol (or streptomycin) for the first 2 months, followed by isoniazid and rifampicin for 7-10 additional months, plus adjunctive corticosteroids tapered over 6-8 weeks 1, 2

Initial Intensive Phase (First 2 Months)

• The initial phase for adults consists of isoniazid, rifampicin, pyrazinamide, and a fourth drug, with ethambutol preferred over streptomycin based on expert opinion, as both options are acceptable but have different considerations for use 1, 3
• The ATS/CDC/IDSA guidelines state that ethambutol is preferred as the fourth drug for adults due to its penetration into the meninges during early treatment stages 1

Continuation Phase (7-10 Additional Months)

• After completing 2 months of four-drug therapy for drug-susceptible TB meningitis, the British Thoracic Society recommends continuing isoniazid and rifampicin for 7-10 additional months, with a total treatment duration of 9-12 months 1, 4
• The total treatment duration is recommended to be 9-12 months, with the British Thoracic Society recommending the full 12-month duration 1, 3, 4

Adjunctive Corticosteroid Therapy

• The use of adjunctive corticosteroids is strongly recommended for all patients with TB meningitis, based on mortality benefit demonstrated in systematic reviews, with dexamethasone or prednisolone tapered over 6-8 weeks 1, 2, 3, 4
• The evidence strength for this recommendation is strong, with moderate certainty in evidence 2

Pediatric Considerations

• For children with TB meningitis, the regimen differs slightly, with the initial phase consisting of isoniazid, rifampicin, pyrazinamide, and ethionamide or an aminoglycoside, followed by isoniazid and rifampicin for 7-10 months 1, 4
• The American Academy of Pediatrics recommends ethionamide or an aminoglycoside rather than ethambutol in children due to concerns about monitoring visual acuity 1

Monitoring Requirements

• Clinical and laboratory monitoring should include repeated lumbar punctures to monitor CSF cell count, glucose, and protein, especially early in therapy, as well as regular neurological assessment for improvement or deterioration 1, 2, 4
• Hepatotoxicity monitoring is also necessary given the hepatotoxic potential of isoniazid, rifampicin, and pyrazinamide 3

Neurosurgical Referral Indications

• Immediate neurosurgical consultation is warranted for hydrocephalus, tuberculous cerebral abscess, or paraparesis 1, 4

Critical Pitfalls to Avoid

• Inadequate treatment duration is the most common error, with TB meningitis requiring 9-12 months of treatment, not the 6 months used for pulmonary TB 4, 3
• Insufficient drug penetration into CSF can occur if the wrong drugs are selected, with isoniazid, pyrazinamide, and ethionamide penetrating well into CSF, while rifampicin penetrates less well but remains essential 4, 3

Emerging Evidence

• Higher doses of intravenous rifampicin and fluoroquinolones are being evaluated in ongoing trials to potentially improve outcomes and shorten treatment duration, but these remain investigational and should not replace standard therapy outside of clinical trials 1, 4